Maze Therapeutics reported net income of -$44.73M for the quarter ended Jun 2026. This income statement covers 10 quarters of results from Mar 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 2.42M | 2.42M | 2.44M | 2.45M | 28.63M | 43.85M | 48.08M | 49.34M | 49.74M | 55.50M |
| Revenue & cost | ||||||||||
| Revenue | 165.00M | 2.50M | 20.00M | |||||||
| Gross Profit | -1.19M | 18.21M | ||||||||
| Operating items | ||||||||||
| Research & DevelopmentR&D | 21.88M | 19.55M | 19.86M | 22.22M | 27.58M | 28.11M | 25.19M | 27.57M | 34.15M | 34.94M |
| Selling, General & AdministrativeSG&A | 6.14M | 5.90M | 6.87M | 7.51M | 7.82M | 8.37M | 7.78M | 10.49M | 12.40M | 13.10M |
| Operating ExpensesOpex | 28.01M | 25.45M | 26.73M | 29.73M | 35.40M | 36.47M | 32.97M | 38.06M | 46.55M | 48.03M |
| Operating IncomeOp. Inc | -28.01M | 139.56M | -24.23M | -29.73M | -35.40M | -36.47M | -32.97M | -38.06M | -26.55M | -48.03M |
| EBIT | -28.01M | 139.56M | -24.23M | -29.73M | -35.40M | -36.47M | -32.97M | -38.06M | -26.55M | -48.03M |
| Non-operating items | ||||||||||
| Non Operating Interest Expenses | 0.87M | 0.93M | ||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.28M | 1.01M | 1.85M | 1.52M | 2.62M | 2.79M | 2.88M | 3.49M | 3.21M | 4.24M |
| Other Non Operating IncomeOther Non Op Inc. | -4.76M | 0.22M | -2.65M | -1.64M | 2.62M | 2.79M | 1.90M | 2.35M | 3.31M | |
| Net income details | ||||||||||
| EBT | -27.73M | 140.78M | -25.03M | -29.85M | -32.79M | -33.68M | -30.09M | -34.57M | -24.21M | -44.73M |
| Tax ProvisionsTaxes | 1.73M | -0.30M | 9.77M | -27.54M | ||||||
| Profit After TaxPAT | -32.49M | 139.06M | -24.75M | -29.58M | -32.79M | -33.68M | -30.09M | -34.57M | -24.21M | -44.73M |
| Income from Continuing OperationsIncome (Continuing) | -27.73M | 139.06M | -24.73M | -39.62M | -32.79M | -33.68M | -30.09M | -7.03M | -24.21M | -44.73M |
| Consolidated Net IncomeConsol Net Inc. | -27.73M | 139.06M | -24.73M | -39.62M | -32.79M | -33.68M | -30.09M | -7.03M | -24.21M | -44.73M |
| Income towards Parent CompanyParent Net Inc | -27.73M | 139.06M | -24.73M | -39.62M | -32.79M | -33.68M | -30.09M | -7.03M | -24.21M | -44.73M |
| Net Income towards Common StockholdersNet Income | -27.73M | 139.06M | -24.73M | -39.62M | -32.79M | -33.68M | -30.09M | -7.03M | -24.21M | -44.73M |
| Additional items | ||||||||||
| EPS (Basic) | -11.87 | 58.20 | -10.24 | -16.54 | -1.15 | -0.77 | -0.66 | -0.16 | -0.45 | -0.76 |
| EPS (Diluted) | -11.87 | 32.23 | -10.24 | -14.51 | -1.15 | -0.77 | -0.66 | -0.16 | -0.45 | -0.76 |
| Shares Outstanding | 2.34M | 2.39M | 2.42M | 2.40M | 28.63M | 43.80M | 45.78M | 42.98M | 53.90M | 59.00M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 2.34M | 4.31M | 2.42M | 2.73M | 28.63M | 43.80M | 45.78M | 42.98M | 53.90M | 59.00M |
| EBITDA | -28.01M | 139.56M | -24.23M | -29.73M | -35.40M | -36.47M | -32.97M | -38.06M | -26.55M | -48.03M |
| Interest ExpensesInt Expense | 0.87M | 0.93M | ||||||||
| Tax Rate | 1.23 | 1.20 | -32.72 | 79.65 |